Hansa Biopharma has closed a €115 million licensing transaction with SERB Pharmaceuticals for its kidney transplant drug in Europe and MENA. Idefirix is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by… Read More
Hansa Biopharma has announced positive topline results from a study investigating Idefirix (imlifidase) in patients who have undergone HLA-incompatible kidney transplantation. The biopharmaceutical company announced the primary objective of the post-authorisation efficacy study (PAES) was met, with 90% of highly sensitised kidney transplant patients achieving one‑year graft failure‑free survival – following Idefirix pre‑treatment to convert… Read More
Hansa Biopharma and SERB have entered a licensing agreement worth €115 million for the development and commercialisation of a treatment for kidney transplant patients. Idefirix (imlifidase) is a first-in-class treatment that targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six… Read More
Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More
Hansa Biopharma has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with its imlifidase prior to receiving Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial. After one dose of imlifidase, three patients experienced a rapid reduction of IgG antibodies, to levels ≥95% less… Read More
